RLFTY

MindMaze Therapeutics Holding SA

Price Chart

Latest Quote

$0.42

+0.00 (+0.00%)

Current Price

Previous Close	$0.42
Open	$0.42
Day High	$0.42
Day Low	$0.42
Volume	3,500

Fetched: 2026-06-16T21:39:29

Stock Information

Note: Financial values converted from CHF to USD

Shares Outstanding	157.60M
Revenue	$810K
Net Income	$-12.50M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$66.59M
EPS (TTM)	$-0.60
Exchange	OQB

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Sales	$810K
Income	$-12.50M
Book/sh	$3.26
Employees	10

Financial Ratios

Quick Ratio	1.05
Current Ratio	1.20

Returns & Margins

ROA	-25.46%
ROE	-51.56%
Gross Margin	92.06%
Operating Margin	-1637.85%

Ownership

Insider & Institutional transactions data not available

Valuation Ratios

P/S	103.72
P/B	0.13

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$1.01
SMA50	$1.40
ATR	0.0936

Shares Float

52.40M

Performance History

Week	+0.00%
Month	+54.71%
Quarter	-55.71%
YTD	-85.02%
10 Years	-71.83%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-15	$0.42	0
2026-06-12	$0.42	0
2026-06-11	$0.42	0
2026-06-10	$0.42	0
2026-06-09	$0.42	0
2026-06-08	$0.42	0
2026-06-05	$0.42	0
2026-06-04	$0.42	0
2026-06-03	$0.42	0
2026-06-02	$0.42	0
2026-06-01	$0.42	7,000
2026-05-29	$1.73	0
2026-05-28	$1.73	0
2026-05-27	$1.73	0
2026-05-26	$1.73	0
2026-05-22	$1.73	0
2026-05-21	$1.73	0
2026-05-20	$1.73	0
2026-05-19	$1.73	0
2026-05-18	$1.73	0

About MindMaze Therapeutics Holding SA

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

📰 Latest News

No news articles available at the moment. Check back later for updates on RLFTY.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31
Revenue
Reconciled Cost Of Revenue	$65,024	$0
Cost Of Revenue	$65,024	$0
Total Revenue	$818,533	$0
Operating Revenue	$818,533	$0
Expenses
Interest Expense	$339,143	$0
Total Expenses	$14,224,879	$2,550
Net Non Operating Interest Income Expense	$39,524	$1,275
Total Other Finance Cost	$19,125	-
Interest Expense Non Operating	$339,143	$0
Operating Expense	$14,159,856	$2,550
Selling And Marketing Expense	$1,528,693	$0
General And Administrative Expense	$5,887,828	$2,550
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-12,629,887	$-1,275
Net Interest Income	$39,524	$1,275
Interest Income	$397,792	$1,275
Normalized Income	$-12,629,887	$-1,275
Net Income From Continuing And Discontinued Operation	$-12,629,887	$-1,275
Total Operating Income As Reported	$-13,406,346	$-2,550
Net Income Common Stockholders	$-12,629,887	$-1,275
Net Income	$-12,629,887	$-1,275
Net Income Including Noncontrolling Interests	$-12,629,887	$-1,275
Net Income Continuous Operations	$-12,629,887	$-1,275
Pretax Income	$-12,629,887	$-1,275
Interest Income Non Operating	$397,792	$1,275
Operating Income	$-13,406,346	$-2,550
Gross Profit	$753,509	$0
Per Share
Diluted EPS	-	$0.00
Basic EPS	-	$0.00
Other
Tax Effect Of Unusual Items	$0	$0
Tax Rate For Calcs	$0	$0
Normalized EBITDA (Bullshit earnings)	$-10,201,063	$-1,275
Reconciled Depreciation	$2,089,682	$0
EBITDA (Bullshit earnings)	$-10,201,063	$-1,275
EBIT	$-12,290,745	$-1,275
Diluted NI Availto Com Stockholders	$-12,629,887	$-1,275
Otherunder Preferred Stock Dividend	$0	$0
Tax Provision	$0	$0
Research And Development	$6,743,335	$0
Selling General And Administration	$7,416,521	$2,550
Diluted Average Shares	-	$15,988,727
Basic Average Shares	-	$15,988,727

Fetched: 2026-04-25

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31
Assets
Net Tangible Assets	$2,623,895	$109,648
Total Assets	$65,699,384	$118,573
Total Non Current Assets	$48,934,758	$118,573
Other Non Current Assets	$142,797	$118,573
Goodwill And Other Intangible Assets	$46,259,864	$0
Other Intangible Assets	$10,055,716	-
Current Assets	$16,764,627	$0
Prepaid Assets	$731,835	$0
Inventory	$1,456,020	$0
Other Receivables	$1,194,650	-
Accounts Receivable	$1,304,298	$0
Allowance For Doubtful Accounts Receivable	$-214,196	$0
Gross Accounts Receivable	$1,518,493	$0
Cash Cash Equivalents And Short Term Investments	$12,077,824	$0
Cash And Cash Equivalents	$12,077,824	$0
Debt
Total Debt	$2,302,602	$0
Long Term Debt And Capital Lease Obligation	$1,500,644	$0
Current Debt And Capital Lease Obligation	$801,958	$0
Liabilities
Total Liabilities Net Minority Interest	$16,815,625	$8,925
Total Non Current Liabilities Net Minority Interest	$2,880,165	$6,375
Current Liabilities	$13,935,460	$2,550
Payables	$5,120,294	$2,550
Other Payable	$2,385,475	-
Accounts Payable	$2,734,818	$2,550
Equity
Common Stock Equity	$48,883,759	$109,648
Total Equity Gross Minority Interest	$48,883,759	$109,648
Stockholders Equity	$48,883,759	$109,648
Retained Earnings	$-13,607,792	$-17,850
Other
Treasury Shares Number	$1,912,968	-
Ordinary Shares Number	$194,563,562	-
Share Issued	$196,476,530	-
Tangible Book Value	$2,623,895	$109,648
Invested Capital	$48,883,759	$109,648
Working Capital	$2,829,166	$-2,550
Capital Lease Obligations	$2,302,602	$0
Total Capitalization	$48,883,759	$109,648
Treasury Stock	$191,246	$191,246
Additional Paid In Capital	$25,820,763	$-1,471,319
Capital Stock	$19,647,342	$1,790,063
Common Stock	$19,647,342	$1,790,063
Non Current Pension And Other Postretirement Benefit Plans	$1,379,521	$0
Long Term Capital Lease Obligation	$1,500,644	$0
Current Capital Lease Obligation	$801,958	$0
Goodwill	$36,204,148	$0
Net PPE	$2,532,097	$0
Accumulated Depreciation	$0	$0
Gross PPE	$2,532,097	$0
Other Properties	$725,460	-
Buildings And Improvements	$1,806,637	$0
Properties	$0	$0
Inventories Adjustments Allowances	$-331,493	$0
Finished Goods	$246,070	$0
Work In Process	$304,719	$0
Raw Materials	$1,236,724	$0

Fetched: 2026-04-25

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31
Free Cash Flow
Free Cash Flow	$-9,218,058	$-3,825
Operating Activities
Operating Cash Flow	$-9,190,009	$-3,825
Investing Activities
Capital Expenditure	$-28,049	-
Investing Cash Flow	$4,646,003	$-2,550
Net Other Investing Changes	$-7,925,235	-
Financing Activities
Financing Cash Flow	$16,589,955	$0
Net Other Financing Charges	$16,930,373	-
Other
End Cash Position	$12,077,824	$0
Beginning Cash Position	$0	$6,375
Effect Of Exchange Rate Changes	$31,874	$0
Changes In Cash	$12,045,950	$-6,375
Interest Received Cfi	$397,792	$0
Net Investment Purchase And Sale	$0	$-2,550
Sale Of Investment	$0	$3,825
Purchase Of Investment	$0	$-6,375
Net Business Purchase And Sale	$12,201,496	$0
Sale Of Business	$12,201,496	$0
Net PPE Purchase And Sale	$-28,049	$0
Purchase Of PPE	$-28,049	$0
Interest Paid Cfo	$-99,448	$0
Change In Working Capital	$1,076,078	$0
Change In Other Current Assets	$-258,820	$0
Change In Accrued Expense	$-420,741	$0
Change In Payable	$2,121,556	-
Change In Receivables	$-365,917	$0
Other Non Cash Items	$-45,899	$-2,550
Depreciation And Amortization	$2,089,682	$0
Depreciation	$2,089,682	-
Pension And Employee Benefit Expense	$419,466	$0
Net Income From Continuing Operations	$-12,629,887	$-1,275

Fetched: 2026-04-25